Clinical Use of IDegLira: Initiation to Titration After Basal Insulin
Open Access
- 1 January 2020
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 38 (1), 62-70
- https://doi.org/10.2337/cd19-0015
Abstract
Delayed treatment intensification is common in U.S. patients with type 2 diabetes uncontrolled on basal insulin. Concerns about weight gain, hypoglycemia, increased regimen complexity, and additional copayments may lead to reluctance to initiate prandial insulin. IDegLira is a titratable, fixed-ratio coformulation that combines the advantages of insulin degludec and the glucagon-like peptide 1 receptor agonist liraglutide in a single once-daily injection and mitigates the side effects associated with each component. Clinical trials have demonstrated that IDegLira improves glycemic control without the increased risk of hypoglycemia and weight gain observed with basal insulin up-titration and the addition of prandial insulin, and this is achieved using twice-weekly titration. Clinical trials and real-world studies have also shown that IDegLira has the potential to reduce therapeutic and titration inertia. However, better outcomes could be achieved with IDegLira initiation in suitable patients with timely titration and by providers sharing their experience with this combination product. This review describes considerations for initiation, titration, and intensification of IDegLira in patients previously receiving basal insulin.Keywords
This publication has 40 references indexed in Scilit:
- Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first‐year report from JapanJournal of Diabetes Investigation, 2015
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesThe Lancet Diabetes & Endocrinology, 2014
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)Diabetes Care, 2014
- Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort studyJournal of Medical Economics, 2013
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013
- The rationale for combining GLP‐1 receptor agonists with basal insulinThe Medical Journal of Australia, 2013
- Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced dosesCurrent Medical Research and Opinion, 2012
- Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic reviewDiabetes, Metabolic Syndrome and Obesity, 2012
- Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findingsDiabetes, Obesity and Metabolism, 2012
- Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the LiteratureJournal of General Internal Medicine, 2007